International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(3):192-198.

Absolute and Functional Iron Deficiency Anemia among Different Tumors in Cancer Patients in South Part of Iran, 2014
Seyed Mehdi Hashemi, Mohammad Ali Mashhadi, Mehdi Mohammadi, Maryam Ebrahimi, Abolghasem Allahyari, Seyed Hossein Soleimanzadeh Mousavi




Background: Anemia is a common problem in cancer patients. This study aimed to investigate the frequency rate of absolute and functional iron deficiency anemia among different tumors and its distribution in different stages of cancer in solid tumors.

Subjects and Methods:This study was performed on 597 patients with cancer referred to Ali-Ebne-Abitaleb Hospital in Zahedan. Laboratory tests included serum iron, transferrin saturation, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and complete blood count (CBC). The malignancy type and stages were recorded. Data were analysed using SPSS statistics software (Ver.19).

Results: Four hundred and fifty-seven patients (76.5 %) diagnosed with solid tumors and 140 (23.5%) suffered from hematologic malignancies. Among patients with solid tumors, functional iron deficiency had the highest rate (300 patients had anemia and 243 (53.2%) of whom werefunctionally iron deficient), but in hematologic malignancies most of patients had not iron deficiency (66 patients had not iron deficiency against 12 patients had absolute iron deficiency and 62 patients had functional iron deficiency anemia) (P-value=0.021). No significant differences were observed among the various stages of cancers in terms of degrees of iron deficiency (P>0.05).

Conclusion: The results of the study showed that solid tumors had a higher rate of absolute and functional iron deficiency anemia, compared to hematologic malignancies. But there was no difference between the different stages of the disease.



Irondeficiency anemia, Cancer, Hematologic malignancies, Chemotherapy

Full Text:



Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:11S-26S.

Groopman J, Itri L. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91: 1616–34.

Mercadante S, Gebbia V, Marrazzo A, et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000; 26: 303–11.

Cella D, Glaspy J, Dobrez D. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol. 2003; 14: 511-19.

Harrison LB, Shasha D, White C, et al. Radiotherapy-associated anemia: the scope of the problem. Oncologist. 2000; 5: 1–7.

Ludwig H, Strasser K. Symptomatology of anemia. SeminOncol. 2001; 28: 7–14.

Caro J, Salas M, Ward A. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91: 2214–21.

Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. TransfusClin Biol. 2005; 12(1): 5–10.

Shen JG, Cheong JH, Hyung WJ. Pretreatment anemia is associated with poorer survival in patients with stage I and II gastric cancer. J SurgOncol. 2005; 91: 126–30.

Thomas DW1, Hinchliffe RF, Briggs C, et al. British Committee Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013; 161(5):639-48.

Ludwig H, Müldür E, Endler G, et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013; 24(7):1886-92.

Zeighami Mohammadi SH, Houshmand P, Djafari ² F, et al. The relationship between anemia and severity of fatigue and quality of life in cancer patients undergoing chemotherapy.nmj. 2008; 16 (2):43-53

Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica. 2002; 87: 1209–1221.

Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am SocNephrol. 2006; 1: S4–S8.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005; 352: 1011–1023.

Robertson KA, Hutchinson SM. Assessment of iron status and the role for iron replacement therapy in anaemic cancer patients under the care of a specialist palliative care unit. Palliat Med. 2009; 23: 406–409.

Spielmann M, Luporsi E, Ray-Coquard, et al. Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009–2010: the AnemOnHe study. Eur J Cancer. 2011; 48: 101–107.

Ludwig H, Aapro M, Beguin Y, et al. Frequent use of blood transfusions in current treatment practice for chemotherapy-induced anemia counteracts treatment recommendations aiming for less transfusions. Haematologica. 2011; 96: abstract 407.

Kuvibidila SR, Gauthier T, Rayford W. Serum ferritin levels and transferrin saturation in men with prostate cancer. J Natl Med Assoc. 2004; 96: 641–649.

Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis. 2005; 7: 398–402.

Poddar N, Raza S, Sharma B, et al. Small bowel adenocarcinoma presenting with refractory iron deficiency anemia - case report and review of literature. Case Rep Oncol. 2011; 4(3):458-63.

Zhen L, Zhe S, Zhenning W, et al. Iron-deficiency anemia: a predictor of diminished disease-free survival of T3N0M0 stage colon cancer. J SurgOncol. 2012; 105(4):371-5.

Sideris M, Adams K, Moorhead J, et al. BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia. Anticancer Res. 2015; 35(4):2345-50.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.